Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

doi:10.1007/s00005-020-00601-6

	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors
	Yan, Yan 1; Zhang, Li 2,3; Zuo, Yun 1; Qian, Heya 1; Liu, Chang 4
刊名	ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
	2020-11-13
卷号	68 期号:6 页码:15
关键词	Immune checkpoints PD-1 PD-L1 Monoclonal antibody Immunotherapy
ISSN号	0004-069X
DOI	10.1007/s00005-020-00601-6
通讯作者	Zhang, Li(lz3@email.sc.edu) ; Liu, Chang(hichang813@uri.edu)
英文摘要	Programmed cell death protein 1 (PD-1) and its ligand PD-L1 are critical for the regulation of T cell exhaustion and activity suppression. Tumor cells expressing immune checkpoints including PD-L1 escape monitoring of T cells from the host immune system. Checkpoint inhibitors are highly promising therapies that function as tumor-suppressing factors via modulation of tumor cell-immune cell interactions as well as boosting T cell-mediated anti-tumor immunity. Notably, PD-1 or PD-L1 monoclonal antibody (mAb) has demonstrated promising therapeutic effects in clinical studies of many types of cancer. These mAbs have caused significant tumor regression with impressive anti-tumor response rates as well as a favorable safety profile in cancer patients. Furthermore, the combination of PD-1/PD-L1 mAbs with other types of anti-tumor agents has also developed to boost the anti-tumor responses and enhance therapeutic effects in cancer patients. This review clarifies the mechanisms of PD-1/PD-L1-mediated anti-cancer immune responses and some clinical studies of mAbs targeting PD-1/PD-L1. The challenges and future of PD-1/PD-L1 blockade therapy are also discussed.
资助项目	Social Development of Science and Technology Bureau of Zhangjiagang City[ZKS1734] ; Project of Diagnosis and Treatment Technology for Key Clinical Diseases of Suzhou[LCZX201617]
WOS关键词	PROGRAMMED DEATH-1 BLOCKADE ; T-CELL EXHAUSTION ; ANTI-PD-L1 ANTIBODY ; OPEN-LABEL ; B7 FAMILY ; PHASE-I ; ACQUIRED-RESISTANCE ; ADVANCED MELANOMA ; PD-1 BLOCKADE ; SINGLE-GROUP
WOS研究方向	Immunology
语种	英语
出版者	SPRINGER BASEL AG
WOS记录号	WOS:000594672200002
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/296200]
专题	中国科学院上海药物研究所
通讯作者	Zhang, Li; Liu, Chang
作者单位	1.Soochow Univ, Affiliated Zhangjiagang Hosp, Zhangjiagang 215600, Jiangsu, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 3.Univ South Carolina, Coll Pharm, Columbia, SC 29208 USA 4.Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA
推荐引用方式 GB/T 7714	Yan, Yan,Zhang, Li,Zuo, Yun,et al. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors[J]. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS,2020,68(6):15.
APA	Yan, Yan,Zhang, Li,Zuo, Yun,Qian, Heya,&Liu, Chang.(2020).Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS,68(6),15.
MLA	Yan, Yan,et al."Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors".ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS 68.6(2020):15.